Psychiatry Review 2017: The Complex Puzzle of Addiction, Neuroscience Frontiers

Date:

Thursday, October 26, 2017 to Friday, October 27, 2017

Location:

The Commons Hotel

This year’s Psychiatry Review conference will provide a guide to the diagnosis, epidemiology, risks, and management of substance use disorders and other psychiatric disorders that commonly co-occur with substance use disorders.

Description

The accurate assessment and effective management of patients with complex addictive disorders poses a significant challenge to psychiatric and other healthcare providers. A primary objective of this year’s Psychiatry Review Conference is to provide a guide on how to apply current research in the epidemiology, diagnosis, risk factors, and management of substance use disorders to clinical care. Additionally, recent advances in neuroscience and psychology have shed light on key biological and behavioral mechanisms underlying a range of psychiatric illnesses.  The 2nd portion of CME programming will highlight neuroscience findings that promise to change the practice of Psychiatry. View agenda

Audience

This activity is designed for psychiatrists and other physicians, nurses and nurse practitioners, psychologists, social workers, and other healthcare professionals who manage and treat patients with substance use and other behavioral health conditions.

Key Topics

  • Alcohol Use Disorders
  • Impulse Control Disorders
  • Neuroscience and Psychiatry
  • Opiate Addiction
  • Evidence-Based Treatments

Keynote Presentations

From the War on Drugs to Public Health: 50 Years of Science and Policy in Addressing Addiction
John F. Kelly, PhD
Elizabeth R. Spallin Associate Professor of Psychiatry in Addiction Medicine
Harvard Medical School

Behavioral Addictions:  Clinical Presentation and Evidence-Based Treatments
Jon Grant, JD, MD, MPH
University of Chicago Department of Psychiatry and Behavioral Neuroscience

The New Uncharted World of Drug Abuse
Carol Falkowski
Drug Abuse Dialogues

Educational Objectives

Following completion of this activity, learners should be better able to:

  • Discuss the current problem of substance use and substance use disorders in our community.
  • Describe the evidence-based treatments for substance use and related conditions including  behavioral and new and promising medications.
  • Discuss non-substance related conditions that commonly co-occur with substance use disorders.
  • Describe new and innovative approaches in the treatment of mental health disorders.
  • Elaborate on how neural circuitry and brain imaging may inform mechanisms and relapse  in substance use disorders.

Presented By

University of Minnesota Department of Psychiatry

Course Directors

Sheila Specker, MD
Associate Professor
Department of Psychiatry
University of Minnesota

Justin Anker, PhD
Assistant Professor
Department of Psychiatry
University of Minnesota

 

Accreditation

Joint Accreditation LogoIn support of improving patient care, University of Minnesota, Interprofessional Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Desingation Statements

American Medical Association (AMA)

The University of Minnesota, Interprofessional Continuing Education designates this live activity for a maximum of 12.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)

This activity is awarded up to 12.75 ANCC contact hours

Minnesota Board of Psychology

This activity has been approved by the Minnesota Board of Psychology (Board Assigned Log #201807.010) for 12.75 continuing education hours.

Minnesota Board of Social Work

The University of Minnesota Office of Continuing Professional Development has been approved by the Minnesota Board of Social Work for 12.75 continuing education hours for this training.

Other Healthcare Professionals

Other healthcare professionals who participate in this CE activity may submit this statement of participation to their appropriate accrediting organizations or state boards for consideration of credit. The participant is responsible for determining whether this activity meets the requirements for acceptable continuing education.

Registration

Early Rate: On or Before September 4, 2017

Physician: $425
Other Healthcare Professionals: $300

UMN/M Health
Full-Time Faculty: $125
Resident/Fellow: $0

Regular Rate: On or After September 5, 2017

Physician: $525
Other Healthcare Professionals: $400

UMN/M Health
Full-Time Faculty: $125
Resident/Fellow: $0

Registration includes breakfast and refreshment breaks.

Group Discount

At least 3 registrations from the same group must be submitted to receive a $20 discount per person. Register each person separately online and enter group discount code 3GRP16 into the discount box during checkout. Or email the completed group registration form to cme@umn.edu. NO refunds will be issued if a person from a group has to cancel or does not show up at the conference. Normal refund policy applies for complete group cancellations.

Requests

Special needs, such as dietary restrictions, lactation room, etc. should be requested in advance. These requests cannot always be honored onsite.

How to Register

Cancellation

Photo Release

CPD may take photos/video of participants at CPD events and these may appear in CPD's promotional materials. Your attendance constitutes your permission and consent for photography and video subsequent usage.

 

Location

The Commons Hotel
615 Washington Ave SE
Minneapolis, MN 55414
Phone: 612-379-8888

Parking

Parking costs are not included in registration fees

Exhibit

We gratefully acknowledge the following organizations for their financial contributions to this activity:

  • GeneSight
  • Janssen Pharmaceuticals
  • Nystrom & Associates, Ltd.
  • Rogers Behavioral Health - Minneapolis
  • Shire
  • Takeda Pharmaceuticals

(List current as of 8/8/17)